Mmp2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| MMP2 Protein | |
|---|---|
| Protein Name | Matrix Metalloproteinase-2 |
| Gene | MMP2 |
| UniProt ID | P08253 |
| PDB IDs | 1CK7, 1EAK, 1G5K |
| Molecular Weight | 73.9 kDa |
| Subcellular Localization | Extracellular matrix, Cell surface |
| Protein Family | MMP family (gelatinases) |
The MMP-2 (Matrix Metalloproteinase-2) protein, also known as gelatinase A, is a zinc-dependent endopeptidase that degrades extracellular matrix components. MMP-2 is secreted as a proenzyme (pro-MMP-2) and activated by proteolytic cleavage. In the brain, MMP-2 regulates synaptic plasticity, blood-brain barrier remodeling, and neuroinflammation. While MMP-2 can contribute to amyloid-beta degradation, it also participates in pathological tissue remodeling in Alzheimer's disease. In Parkinson's disease, MMP-2 is involved in dopaminergic neuron survival and disease progression.
MMP-2 (gelatinase A) is a zinc-dependent endopeptidase that degrades extracellular matrix components and is involved in tissue remodeling and neuroinflammation.
MMP2 is a 660-amino acid protein with a signal peptide (1-20), propeptide (21-84) containing a cysteine switch, catalytic domain (85-211) with zinc-binding motif HEXGHNL, fibronectin type II repeats (211-438) for gelatin binding, hinge region (439-469), and hemopexin domain (470-660). The propeptide maintains latency until cleaved for activation.
MMP-2 degrades gelatin (denatured collagen), type IV collagen, elastin, and other ECM components. It is secreted as a proenzyme (pro-MMP-2) and activated by membrane-type MMPs (MT1-MMP/MMP14). MMP-2 is involved in tissue remodeling, wound healing, blood-brain barrier (BBB) breakdown, synaptic plasticity, and neuroinflammation. It plays roles in Aβ degradation in AD and dopaminergic neuron survival in PD.
Elevated MMP-2 is seen in AD (associated with amyloid pathology and BBB dysfunction), PD (dopaminergic region), MS (active lesions), and after stroke/TBI (contributes to secondary damage). MMP-2 deficiency worsens outcomes in some injury models.
Broad-spectrum MMP inhibitors (batimastat, marimastat) failed in cancer trials due to side effects. Selective MMP-2 inhibitors are being developed. Natural compounds (tetrahydroxy stilbene, ebselen) have shown MMP-2 modulating activity. Timing and context-specific effects complicate therapeutic targeting.
The study of Mmp2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
MMP-2 is widely expressed in various tissues:
In the brain, MMP-2 expression is particularly high in:
MMP-2 activation requires a complex cascade:
MMP-2 degrades multiple substrates:
MMP-2 has complex roles in AD:
Protective Effects:
Pathological Effects:
In PD, MMP-2 modulates:
MMP-2 in ALS:
| Compound | Type | Status | Notes |
|---|---|---|---|
| Batimastat | Broad-spectrum | Preclinical | Poor bioavailability |
| Marimastat | Broad-spectrum | Clinical trials | GI side effects |
| Selective inhibitors | MMP-2 specific | Research | In development |
MMP-2 levels as potential biomarkers: